Discovery and Preclinical Antitumor Efficacy Evaluations of LY32262 and LY33169

@article{Corbett2003DiscoveryAP,
  title={Discovery and Preclinical Antitumor Efficacy Evaluations of LY32262 and LY33169},
  author={Thomas H. Corbett and Kathryn White and Lisa Marie Polin and Juiwanna Kushner and Jennifer Paluch and C -Y.T. Shih and Cora Sue Grossman},
  journal={Investigational New Drugs},
  year={2003},
  volume={21},
  pages={33-45}
}
The discoveries of a new antitumor agent (LY32262) (N-[2,4-dichlorobenzoyl]phenylsulfonamide) and a close analog (LY33169) are described. For this discovery, a disk-diffusion-soft-agar-colony-formation-assay was used to screen a portion of the Eli Lilly inventory, with the evaluation of each agent against normal cells, leukemic cells and several solid tumors, including a multidrug-resistant solid tumor (with marked selective cytotoxicity for Colon-38 and Human-Colon-15/MDR compared to normal… CONTINUE READING